<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967236</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0794</org_study_id>
    <nct_id>NCT03967236</nct_id>
  </id_info>
  <brief_title>Impact of Intestinal Virome on Pediatric Inflammatory Bowel Disease</brief_title>
  <acronym>IVOIRE</acronym>
  <official_title>Impact of Intestinal Virome on Pediatric Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last few years, dysbiosis has emerged as a possible trigger of gut inflammation in
      inflammatory bowel disease (IBD) and a promising therapeutic target. The complex diversity of
      microbiota was initially highlighted by the powerful new tools in genetics, including
      next-generation sequencing (NGS). NGS permitted to decipher the composition of bacterial
      intestinal communities, but also that of the gut virome. Since then, the evidence of a
      dynamic instability of the enteric virome in IBD has grown considerably. IBD patients present
      an expansion of bacteriophages (Caudovirales) associated with decreased bacterial diversity.
      Moreover, gut virome richness seems to differ between Crohn's disease (CD) and ulcerative
      colitis (UC) patients. These insights open the gate of new diagnostic, predictive, and
      therapeutic approaches. However, little is known about pediatric IBD gut virome in terms of
      variability and evolution under the influence of different treatments (exclusive enteral
      nutrition, immunosuppressive therapy and biologics). The aim of this study is to evaluate the
      gut family viral diversity and relative abundance of eukaryotes and prokaryotes in paediatric
      IBD patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation over time of change of the gut virome</measure>
    <time_frame>at the inclusion, 6 months and one year</time_frame>
    <description>Abundance measure: number of sequences generated for a given family or species.
Viral isolation, extraction, and amplification of viral nucleic acids from patient's stools.
Next generation sequencing Statistical analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation over time of change of the gut virome</measure>
    <time_frame>at the inclusion, 6 months and one year</time_frame>
    <description>Measure of relative abundance: abundance of a given family or species relative to other species or families in the sample.
eukaryote versus prokaryote virus
Viral isolation, extraction, and amplification of viral nucleic acids from patient's stools.
Next generation sequencing Statistical analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation over time of change of the gut virome</measure>
    <time_frame>at the inclusion, 6 months and one year</time_frame>
    <description>Measure of alpha diversity by the Shannon index which takes into account the number of species present, but also the distribution of these species.
Viral isolation, extraction, and amplification of viral nucleic acids from patient's stools.
Next generation sequencing Statistical analysis</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of stool and blood samples</intervention_name>
    <description>For each visit, stool and blood samples will be collected during a pediatric gastroenterology day hospital stay.
This collection of stool and blood specific IVOIRE study is carried out in the context of examination already planned for the usual care of the patient.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool and blood samples from paediatric inflammatory bowel disease patients.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with nflammatory bowel disease newly treated with anti-TNF therapy in the &quot;Hôpital
        Femme Mère Enfant&quot; center in Lyon
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 6-17 years

          -  Follow-up in pediatric gastroenterology for inflammatory bowel disease :

               -  Crohn's disease

               -  Hemorrhagic rectocolitis

          -  Introduction of anti-TNFa treatment in the Pediatric Gastroenterology Day Hospital of
             the &quot;Hôpital Femme Mère Enfant&quot; service in Lyon

          -  Collection of the non-opposition of at least one of the holders of the parental
             authority present and the child in the medical file

        Exclusion Criteria:

          -  Refusal to participate in the study

          -  Antibiotherapy in the 4 weeks preceding the sampling

          -  Patient with ileostomy or colostomy.

          -  Patient who has undergone extensive bowel resection.

          -  History of intestinal surgery (except appendectomy)

          -  Patient subject to a legal protection measure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rémi DUCLAUX-LORAS, Dr</last_name>
    <phone>04 72 35 70 50</phone>
    <phone_ext>+33</phone_ext>
    <email>remi.duclaux-loras@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de gastroentérologie nutrition, hépatologie pédiatrique - Hôpital Femme Mère Enfant groupement hospitalier Est - HCL</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémi DUCLAUX-LORAS, Dr</last_name>
      <phone>04.72.35.70.50</phone>
      <phone_ext>+33</phone_ext>
      <email>remi.duclaux-loras@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Alain LACHAUX, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara RHOMER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathias RUIZ, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine CHAMBAZ-LEGALL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucile ESPESO, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noel PERETTI, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rémi DUCLAUX-LORAS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

